Evaluate the Effects of Famotidine or Rabeprazole on the PK of Nirogacestat
Trial Parameters
Brief Summary
This study will evaluate the effects of the H2 blocker famotidine or the PPI rabeprazole on the PK of nirogacestat in healthy male participants
Eligibility Criteria
Inclusion Criteria: 1. Participant understands the study procedures, is willing to comply with all study requirements and restrictions, and agrees to participate in the study by providing written informed consent as described in Appendix 1 of the protocol, prior to any study-related procedures being performed. 2. Participant is a male (assigned at birth) between 18 and 55 years of age (inclusive) at the time of informed consent. 3. Participant has a body mass index (BMI) ≥18.0 kg/m2 and ≤32.0 kg/m2 (inclusive) at Screening and a total body weight \>50 kg. 4. Participant is considered to be medically healthy, as determined by a responsible and experienced investigator, based on a clinical evaluation (including medical history, physical examination, clinical laboratory tests, vital sign measurements, and a 12-lead ECG performed, and the results of clinical chemistry, hematology, coagulation, and urinalysis carried out at Screening and Day -1. 5. Participant has alanine aminotransferase (